CMB — Cambium Bio Income Statement
0.000.00%
- AU$1.26m
- AU$1.23m
Annual income statement for Cambium Bio, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
C2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 1.66 | 7.07 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5.42 | 2.36 | 4.54 | 4.21 | 1.35 |
Operating Profit | -5.42 | -0.693 | 2.52 | -4.21 | -1.35 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.02 | -1.07 | 2.76 | -4.31 | -1.69 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.02 | -1.07 | 2.76 | -4.31 | -1.69 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.02 | -1.07 | 2.76 | -4.31 | -1.69 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.02 | -1.07 | 2.76 | -4.31 | -1.69 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.88 | -1.1 | 0.918 | -1.35 | -0.508 |